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Translational relevance  36 
Esophageal cancer ranks as the 6th most frequent cause of cancer death in the world. 37 
Neoadjuvant or adjuvant chemotherapy is widely used in treatment of esophageal cancer but 38 
development of chemoresistance can compromise treatment efficacy or even result in 39 
recurrence. A better understanding of the molecular mechanisms and development of novel 40 
strategies to improve treatment outcome is urgently needed. This study provides the first 41 
evidence that Id1 confers 5-fluorouracil (5-FU) chemoresistance through E2F1-dependent 42 
induction of IGF2 and thymidylate synthase, a critical target of anti-cancer drugs especially 43 
5-FU. Analysis of gene expressions, clinical data and multiple GEO datasets reveals that 44 
concurrent high expression of Id1 and IGF2 is associated with poor survival in esophageal, 45 
colon, liver, lung, and breast cancers. By providing solid evidence on the importance of the 46 
Id1-E2F1-IGF2 regulatory axis in promoting chemoresistance, our study offers new insights 47 
into developing novel therapeutic interventions and prognostic strategies for esophageal 48 
cancer. 49 
  50 
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Abstract 51 
Purpose: Chemoresistance is a major obstacle in cancer therapy. We found that fluorouracil 52 
(5-FU)-resistant esophageal squamous cell carcinoma cell lines, established through exposure 53 
to increasing concentrations of 5-FU, showed upregulation of Id1, IGF2, and E2F1. We 54 
hypothesized that these genes may play an important role in cancer chemoresistance. 55 
Experimental Design: In vitro and in vivo functional assays were performed to study the 56 
effects of Id1-E2F1-IGF2 signaling in chemoresistance. Quantitative real-time PCR, Western 57 
blot, immunoprecipitation, chromatin immunoprecipitation, and dual-luciferase reporter 58 
assays were used to investigate the molecular mechanisms by which Id1 regulates E2F1 and 59 
by which E2F1 regulates IGF2. Clinical specimens, tumor tissue microarray and Gene 60 
Expression Omnibus datasets were used to analyze the correlations between gene expressions, 61 
and the relationships between expression profiles and patient survival outcomes. 62 
Results: Id1 conferred 5-FU chemoresistance through E2F1-dependent induction of 63 
thymidylate synthase expression in esophageal cancer cells and tumor xenografts. 64 
Mechanistically, Id1 protects E2F1 protein from degradation and increases its expression by 65 
binding competitively to Cdc20, whereas E2F1 mediates Id1-induced upregulation of IGF2 66 
by binding directly to the IGF2 promoter and activating its transcription. The expression level 67 
of E2F1 was positively correlated with that of Id1 and IGF2 in human cancers. More 68 
importantly, concurrent high expression of Id1 and IGF2 was associated with unfavorable 69 
patient survival in multiple cancer types. 70 
Conclusions: Our findings define an intricate E2F1-dependent mechanism by which Id1 71 
increases thymidylate synthase and IGF2 expressions to promote cancer chemoresistance. 72 
The Id1-E2F1-IGF2 regulatory axis has important implications for cancer prognosis and 73 
treatment.  74 
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Introduction  75 
Chemotherapy, alone or in combination with other treatment modalities, is widely used in 76 
cancer treatment. However, development of resistance to chemotherapeutic drugs remains a 77 
serious challenge in the management of human cancer because this may result in disease 78 
recurrence and more aggressive tumor phenotypes. A better understanding of the genetic 79 
alterations and molecular mechanisms responsible for cancer chemoresistance, as well as 80 
novel strategies to improve treatment outcome are urgently needed.  81 
We recently succeeded in establishing cell line models of acquired chemoresistance by 82 
treating esophageal cancer cells with increasing concentrations of 5-fluorouracil (5-FU) up to 83 
80 μM for 18 months.  Besides upregulation of thymidylate synthase (TS) (1) , which is an 84 
essential enzyme for de novo synthesis of thymidylates and a critical target of 5-FU (2, 3) , 85 
and activation of AKT (4), we have obtained novel evidence in the present study that there 86 
was significant increase in the expression of E2F1, inhibitor of DNA binding 1 (Id1), and 87 
insulin-like growth factor 2 (IGF2) proteins in these 5-FU-resistant (FR) cell lines. The 88 
increase of E2F1 in the FR cell lines was not surprising because E2F1 has been reported to 89 
increase the resistance of cancer cells to 5-FU, and to directly induce the transcription and 90 
expression of TS (5, 6). However, the functions of Id1 and IGF2 in 5-FU resistance have not 91 
been reported. Our previous study showed that Id1 overexpression upregulates IGF2 in a 92 
variety of cancer cells, and that blockade of insulin-like growth factor type 1 receptor 93 
(IGF1R), which is the main receptor that mediates the biological functions of IGF2, can 94 
inhibit the PI3K/AKT pathway and sensitize esophageal cancer cells to 5-FU treatment (1). 95 
Whether there is a causal link between increased Id1/IGF2 and E2F1 upregulation in 5-FU 96 
chemoresistance warrants investigation. 97 
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As a transcription factor, E2F1 is capable of directly binding to DNA consensus sequences 98 
to exert transcriptional effects. Recently, the anaphase promoting complex/cyclosome 99 
(APC/C)-associated protein Cdc20 (cell division cycle protein 20) , which is an interaction 100 
partner of Id1 (7), was found to target E2F1 for degradation (8), but the significance and 101 
regulation of this mechanism in cancer are yet unknown. We therefore hypothesize that there 102 
is competitive binding between Id1 and E2F1 to Cdc20 in cancer cells, so that increased Id1 103 
in FR cells may stabilize E2F1 protein and protect it from degradation. To test this hypothesis, 104 
we investigated whether Id1 modulates E2F1 protein stability, and whether this mechanism 105 
regulates TS expression and 5-FU chemoresistance. In addition, gain- and loss-of function 106 
experiments were carried out to demonstrate the effect of IGF2 on TS expression and the 107 
significance of IGF2 in acquired chemoresistance in esophageal squamous cell carcinoma 108 
(ESCC) cells. We also aim to decipher the mechanism by which Id1 regulates IGF2, and to 109 
determine if E2F1 mediates the regulation of IGF2 by Id1.  110 
  111 
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Materials and Methods 112 
Cell lines 113 
Human ESCC cell lines KYSE150, KYSE270, KYSE410 (DSMZ, Braunschweig, Germany) 114 
(9), T.Tn (JCRB Cell Bank, Osaka, Japan) (10), human colon carcinoma cell line Caco-2 115 
(ATCC, Rockville, MD) and human hepatocarcinoma cell line SMMC-7721 (CAMS, Beijing, 116 
China) were maintained in RPMI 1640 (Sigma, St. Louis, MO) supplemented with 10% fetal 117 
bovine serum (Invitrogen, Gaithersburg, MD) at 37ºC in 5% CO2. The 293 phoenix cells 118 
(ATCC) were maintained in DMEM (Sigma) supplemented with 10% fetal bovine serum. All 119 
cell lines were authenticated by short tandem repeat profiling. 120 
 121 
Primary tumor tissues and tissue microarray  122 
Human ESCC tumors and the corresponding adjacent normal esophageal tissues were 123 
collected with informed consent and Institutional Review Board approval from 50 patients 124 
undergoing surgical resection of primary esophageal tumor at Queen Mary Hospital in Hong 125 
Kong from 2011 to 2014, and at the First Affiliated Hospital, Zhengzhou University in 126 
Zhengzhou, China, from 2008 to 2010. All specimens were snap-frozen in liquid nitrogen and 127 
stored at -80ºC. Total RNA isolated from another cohort of human ESCC tumors with 128 
complete patient clinical data, collected from 35 patients at Queen Mary Hospital from 2003 129 
to 2007, was used for survival correlation analysis. A tissue microarray (TMA) containing 35 130 
cases of human ESCC in duplicated cores (Catalogue no. ES802, Biomax, Rockville, MD) 131 
was also used to evaluate the correlation between E2F1 and IGF2. 132 
 133 
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In vitro BrdU cell proliferation, migration, Western blot, ELISA, quantitative real-time 134 
PCR, ChIP, immunoprecipitation, and luciferase reporter assays 135 
Cell proliferation was determined based on BrdU incoporation. Transwell chambers 136 
(Millipore, Billerica, MA) were used to examine cell migration (11). Preparation of cell and 137 
tumor lysates, and details of immunoblotting were described previously (12).  More detailed 138 
experimental procedures can be found in the Supplementary Materials and Methods. 139 
 140 
In vivo tumorigenicity in nude mice 141 
Female BALB/c nude mice aged 6-8 weeks were maintained under standard conditions 142 
according to the institutional guidelines for animal care. All the animal experiments were 143 
approved by the Committee on the Use of Live Animals in Teaching and Research of the 144 
University of Hong Kong. The tumorigenicity experiments were performed as described 145 
previously (4).  146 
 147 
Immunohistochemistry and evaluation of staining 148 
After antigen retrieval and blocking with normal serum, the slides were incubated overnight 149 
at 4 ºC with the primary antibody against E2F1 (#SC-251, Santa Cruz Biotechnology, Santa 150 
Cruz, CA) followed by biotinylated secondary antibodies and peroxidase-conjugated avidin-151 
biotin complex. Immunostaining was visualized using 3, 3’-diaminobenzidine (DAKO) as 152 
chromogen, and then the sections were counterstained with hematoxylin. The E2F1 153 
immunostaining in the TMA was assessed using a grading system based on the percentage of 154 
positive nuclei (13): 0, no nuclear staining; 1, < 10% positive staining; 2, 10-50%; 3, > 50%.  155 
Immunostaining of IGF2 was performed with an anti-human IGF2 antibody (#AF-292-NA) 156 
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from R&D Systems (Minneapolis, MN;) and evaluated as described previously (1). 157 
Specimens assigned scores of 0 to 1 were considered weak, whereas scores 2 to 3 were 158 
considered strong.  159 
 160 
Analysis of gene expression and survival data from cancer patient datasets  161 
Microarray gene expression and survival data of cohorts of ESCC (14), EAC (15, 16), colon 162 
cancer (17, 18), hepatocellular carcinoma (HCC) patients (19), lung cancer (20), and breast 163 
cancer (21, 22), were downloaded from the GEO database (accession numbers GSE23400, 164 
GSE47404, GSE13898, GSE37203, GSE28000, GSE28722, GSE10141, GSE45436, 165 
GSE54236, GSE3141, GSE7849, GSE50948). R scripting was used to extract the expression 166 
values of genes of interests and clinical data from the data matrices as described by Yuen et 167 
al (23, 24). Gene expressions were further divided into high and low levels using median 168 
expression level as the cut-off point for Kaplan-Meier survival analyses. 169 
 170 
Statistical analysis  171 
The data were expressed as the mean ± SD and compared using ANOVA. The expression 172 
level of Id1, E2F1, and IGF2 in tumor samples and matched normal samples was compared 173 
using paired or unpaired t-test. Correlation between E2F1 and Id1 or IGF2 expression in the 174 
frozen tissues and TMA was assessed using Pearson’s rank correlation coefficient and 175 
Fisher’s Exact tests, respectively. The association between the expression level and patient 176 
survival was plotted using the Kaplan-Meier method, and statistical differences were 177 
compared using the log-rank test. P values < 0.05 were deemed significant. All in vitro 178 
experiments and assays were repeated at least three times. 179 
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Results 181 
Up-regulation of Id1, IGF2 and E2F1 in 5-FU-chemoresistant esophageal cancer cell 182 
subpopulation and significance of E2F1 in 5-FU chemoresistance 183 
The PI3K/AKT pathway is one of the most important pathways involved in the development 184 
of chemoresistance. Since our previous study showed that PI3K/AKT can be activated by 185 
Id1-induced IGF2 in cancer cells (1) , we hypothesized that Id1 and IGF2 may have a role in 186 
5-FU resistance. Furthermore, since it was reported that E2F1 expression can increase the 187 
resistance of fibrosarcoma cells to 5-FU (5) , we speculated that E2F1 protein may also be 188 
differentially expressed upon acquisition of 5-FU chemoresistance.  We therefore made use 189 
of 5-FU resistant sublines (designated KYSE150FR and KYSE410FR) which were 190 
established from ESCC cell lines KYSE150 and KYSE410 through continuous treatment 191 
with increasing doses of 5-FU (from 1.25 μM to 80 μM) for over 18 months (Fig. 1A) as cell 192 
models to test our hypothesis.  The proliferation rate and migration ability of FR cells were 193 
similar or slightly higher compared with parental cells (Supplementary Figure S1). Tumor 194 
xenografts that were derived from FR cells were confirmed to exhibit robust resistance to 5-195 
FU in vivo (Fig. 1B). Comparison of the FR cell lines and their parental cell lines showed up-196 
regulation of Id1, IGF2, and E2F1 protein expression (Fig. 1C), as well as increased secretion 197 
of IGF2 in the FR cells (Fig. 1D). Increased mRNA expression levels of Id1 and IGF2, but 198 
not E2F1, were observed in the FR cells (Fig. 1E). ESCC cells with E2F1 overexpression or 199 
knockdown were treated with 5-FU, and then cell proliferation was measured. As expected, 200 
ectopic expression of E2F1 increased TS expression and 5-FU chemoresistance, whereas 201 
repressed expression of E2F1 had the opposite effects (Supplementary Fig. S2). These 202 
findings strongly support the rationale of using these FR sublines as cell models for 203 
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identifying chemoresistance-associated genes, and for studying the roles of Id1 and IGF2 in 204 
regulating 5-FU chemoresistance in ESCC. 205 
 206 
Id1 confers 5-FU chemoresistance through E2F1-dependent induction of thymidylate 207 
synthase expression  208 
Having established that Id1, IGF2 and E2F1 proteins were upregulated in FR cells, our next 209 
questions were whether Id1 plays an important role in 5-FU chemoresistance and whether 210 
E2F1 is involved in mediating this function. Gain- and loss-of function experiments were 211 
carried out to study the effect of Id1 on 5-FU chemoresistance, and on E2F1 and TS 212 
expression in ESCC cells. Rescue experiments were performed to determine whether E2F1 213 
mediates the effect of Id1 in increasing 5-FU resistance. We also determined the clinical 214 
relevance of Id1 and E2F1 by analyzing their protein levels in 50 pairs of primary ESCC 215 
tumors and tumor-adjacent normal tissues by Western blot. The in vitro experiments showed 216 
that ectopic Id1 expression significantly enhanced the resistance of esophageal cancer cells to 217 
5-FU (Supplementary Fig. S3A). Conversely, knockdown of Id1 expression significantly 218 
restored the sensitivity of FR cells to 5-FU (Supplementary Fig. S3B and C). Interestingly, 219 
we found that Id1 overexpression induced (Fig. 2A), whereas Id1 knockdown reduced (Fig. 220 
2B), the expression levels of E2F1 and TS dose-dependently. The rescue experiments showed 221 
that the induction of TS by Id1 was abrogated by two different shRNAs against E2F1 (Fig. 222 
2C, left), and that E2F1 overexpression restored the TS expression in Id1-repressed ESCC 223 
cells (Fig. 2C, right). In addition, higher Id1 and E2F1 expressions were observed in the 224 
majority of tumors compared with the corresponding normal tissues (Supplementary Fig. S4). 225 
There was also a positive correlation between expressions of Id1 and E2F1 in the 50 pairs of 226 
ESCC and normal esophageal tissues (Fig. 2D). Furthermore, our in vitro functional assays 227 
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showed that E2F1 knockdown and overexpression abolished the effects of Id1 overexpression 228 
and knockdown, respectively, on sensitivity of esophageal cancer cells to 5-FU in vitro (Fig. 229 
2E). More importantly, the animal experiments showed that 5-FU treatment which exerted a 230 
markedly repressive effect on the size of vector control tumors had little effect on that of the 231 
Id1-overexpressing tumors, but knockdown of E2F1 significantly reduced the 5-FU 232 
resistance of Id1-overexpressing tumors (Fig. 2F, left; Supplementary Figure S5A). 233 
Conversely, although 5-FU treatment had no effect on growth of tumors derived from FR 234 
cells, there was an obvious response in the KYSE410FR-shId1 tumors, which was abolished 235 
when E2F1 was overexpressed (Fig. 2F, right; Supplementary Figure S5B). Taken together, 236 
these findings consistently showed that Id1 significantly increased TS expression and 5-FU 237 
chemoresistance in esophageal cancer cells through upregulation of E2F1. 238 
 239 
Id1 protects E2F1 protein from degradation and increases its expression by competitive 240 
binding to Cdc20  241 
Given that Id1 interacts with Cdc20 (7) , and that Cdc20 can target E2F1 for proteasomal 242 
degradation (8) , we hypothesized that Id1 might compete with E2F1 for interaction with 243 
Cdc20, therefore stabilizing E2F1 protein. Id1-overexpressing ESCC cells and the 244 
corresponding vector control cells were treated with protein synthesis inhibitor 245 
cycloheximide (CHX) for up to 8 h. Western blot data showed that E2F1 protein degradation 246 
was retarded in the Id1-expressing cells compared with the control cells (Fig. 3A), which 247 
suggests that Id1 overexpression leads to stabilization of E2F1 protein. We then performed 248 
immunoprecipitation on esophageal cancer cells co-transfected with the plasmids expressing 249 
Flag-Cdc20 and HA-Id1, and found that Cdc20 and Id1 were indeed interacting partners in 250 
esophageal cancer cells (Fig. 3B). Meanwhile, the physical interaction between Cdc20 and 251 
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E2F1 in esophageal cancer cells was also determined by immunoprecipitation and Western 252 
blot. HA-tagged E2F1 protein was detected in the Flag-Cdc20 immunoprecipitate in the cells 253 
co-transfected with Flag-Cdc20 and HA-E2F1 (Fig. 3C). In the reverse co-254 
immunoprecipitation experiments, Cdc20 was detectable in E2F1- and Id1-255 
immunoprecipitates, thus confirming that Cdc20 could directly bind to E2F1 and Id1 256 
(Supplementary Figure S6A and B). More importantly, we co-transfected the plasmids 257 
expressing Flag-Cdc20 and HA-E2F1 together with HA-Id1-expressing plasmid or vector 258 
control, and found significantly lower E2F1 level in the Flag-Cdc20 immunoprecipitate of the 259 
Id1 transfectants (Fig. 3D, lane 4 vs lane 3), indicating that Id1-Cdc20 interaction inhibited 260 
the association between Cdc20 and E2F1. Similar results were observed when the cells were 261 
treated with 5-FU (Supplementary Figure S6C). On the other hand, immunoprecipitation 262 
assay failed to reveal any interaction between Id1 and E2F1 in either ESCC parental cells or 263 
FR cells (supplementary Fig. S7). Our results collectively demonstrated that Id1 could protect 264 
E2F1 protein degradation and increase its expression by competitive binding to Cdc20, as 265 
illustrated in Figure 3E.  266 
 267 
E2F1 mediates Id1-induced upregulation of IGF2 by binding directly to IGF2 promoter 268 
Although we have reported that Id1 induces the expression of IGF2 in cancer cells (1), the 269 
mechanism is still unknown. The above findings raised the question of whether there is a link 270 
between the regulation of E2F1 by Id1 and that of IGF2 by Id1. The effect of E2F1 on IGF2 271 
was studied using Western blot. Ectopic E2F1 expression was found to induce IGF2 protein 272 
expression dose-dependently in KYSE150 and KYSE410 (Fig. 4A, left). Transient 273 
transfection of two different shRNAs against E2F1 successfully repressed E2F1 expression 274 
and inhibited IGF2 protein expression in KYSE270 and T.Tn ESCC cells (Fig. 4A, right), 275 
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indicating the positive regulation of IGF2 by E2F1. These effects were confirmed in other 276 
human cancer lines including colon and liver cancer cells (Supplementary Fig. S8). Moreover, 277 
the data from RT-PCR analysis showed that E2F1 overexpression increased (Fig. 4B, left), 278 
whereas E2F1 knockdown decreased (Fig. 4B, middle and right), the mRNA expression of 279 
IGF2 in ESCC cell lines, indicating that E2F1 regulates IGF2 expression at both protein and 280 
mRNA levels. Next, two software programs that predict transcription factor binding sites, 281 
namely Contra V2 and TRRD (25, 26), were used to search for potential E2F1 binding sites 282 
(BS) in the IGF2 promoter region, and three potential binding sites (designated BS1, BS2 and 283 
BS3) were identified by both software, which suggested that E2F1 may bind directly to the 284 
IGF2 promoter and activate IGF2 transcription (Fig. 4C). Then chromatin 285 
immunoprecipitation (ChIP) assay of endogenous E2F1 in esophageal cancer cells, followed 286 
by quantitative PCR, were performed to verify the physical binding of E2F1 to the individual 287 
binding sites on IGF2 promoter. The results showed that the DNA fragments containing BS1 288 
and BS2, but not BS3, were detected in the E2F1-immunoprecipitated DNA fragments (Fig. 289 
4C). To examine whether E2F1 directly activates IGF2 transcription, dual luciferase reporter 290 
assay was conducted by co-transfecting the luciferase reporter plasmid (pGL2-Luc-basic) 291 
containing the IGF2 promoter together with E2F1-expressing plasmid or vector control. The 292 
data showed that the luciferase activity of IGF2 promoter was significantly enhanced when 293 
co-transfected with wild type (WT) E2F1-expressing plasmid, compared with vector control 294 
(Fig. 4D). Mutations in BS1 or BS2, but not BS3, resulted in loss of promoter activity upon 295 
activation by E2F1 (Fig. 4D), indicating that E2F1 activates IGF2 transcription by binding to 296 
the BS1 and BS2, but not BS3 of IGF2. Furthermore, we investigated whether E2F1 mediates 297 
the effect of Id1 on IGF2 expression. Western blot data from KYSE150 and KYSE410 cells 298 
showed that knockdown of E2F1 by two different shRNAs against E2F1 attenuated the 299 
increase in expression levels of E2F1 and IGF2 induced by Id1 overexpression (Fig. 4E). 300 
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Conversely, E2F1 overexpression counteracted the inhibitory effect of Id1-knockdown on 301 
IGF2 expression in KYSE270 and T.Tn cells (Fig. 4F). Together, these results showed that 302 
E2F1, induced by Id1, could directly activate IGF2 transcription. 303 
 304 
E2F1 and IGF2 are overexpressed and positively correlated with each other in human 305 
cancers 306 
IGF2 is overexpressed in 81% of ESCC (27). The direct regulation of IGF2 by E2F1 307 
demonstrated in the in vitro experiments above led us to postulate that E2F1 expression may 308 
be upregulated and positively correlated with IGF2 expression in ESCC. To study the 309 
significance of E2F1 and IGF2 expressions in human esophageal cancer, IGF2 expression 310 
was examined in 50 pairs of primary ESCC tumors and tumor-adjacent normal tissues by 311 
Western blot. Similar to E2F1 described above (Supplementary Fig. S4), higher IGF2 312 
expression was found in the majority of the primary esophageal tumors relative to the 313 
corresponding normal tissues (Fig. 5A, left). The mean expression level of IGF2 in ESCC 314 
was about 4-fold higher than that in the normal esophageal tissue (0.99 ± 0.64 versus 0.28 ± 315 
0.30; P < 0.001) (Fig. 5A, right). More importantly, the 50 pairs of ESCC and normal 316 
esophageal tissues showed a positive correlation between expressions of E2F1 and IGF2 (Fig. 317 
5B). The correlation was further validated by analyzing the immunohistochemical 318 
expressions of E2F1 and IGF2 in a TMA containing 35 cases of primary ESCC tumor tissues 319 
(Fig. 5C). Furthermore, analysis of gene expression profiles of several cohorts of patients 320 
from Gene Expression Omnibus (GEO) database showed strong positive correlation between 321 
E2F1 and IGF2 expression in ESCC, colon, and breast cancers; and modest but statistically 322 
significant correlation in esophageal adenocarcinoma (EAC), hepatocellular carcinoma (HCC) 323 
and lung cancer (Fig. 5D). E2F1 mRNA expression was also positively correlated with TS 324 
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mRNA expression in the same GEO datasets (Supplementary Fig. S9). These results further 325 
support our findings that E2F1 may be important in regulating IGF2 expression and 5-FU 326 
chemoresistance. 327 
 328 
IGF2 plays an important role in regulating esophageal cancer chemoresistance  329 
Although our previous study showed that blockade of the IGF2 receptor IGF1R can sensitize 330 
ESCC cells to 5-FU treatment (1) , the function and mechanism of IGF2 in 5-FU 331 
chemoresistance remained unexplored.  In vitro and in vivo experiments were carried out to 332 
determine if IGF2 is crucial for 5-FU chemoresistance in esophageal cancer. We found that 333 
addition of exogenous IGF2 to ESCC cells not only increased the expression levels of 334 
phosphorylated-AKT (p-AKT) and its downstream target TS (Supplementary Fig. S10A), but 335 
also protected the cells from 5-FU-induced apoptosis and enhanced their resistance to 5-FU, 336 
as indicated by the decrease in 5-FU-induced cleaved caspase-3 expression (Supplementary 337 
Fig. S10B) and increased cell proliferation (Supplementary Fig. S10C). These effects were 338 
abolished by the specific PI3K inhibitor LY294002. In addition, we stably transduced shRNA 339 
against IGF2 into the FR cell lines, KYSE150FR and KYSE410FR, to generate stable cell 340 
lines with repressed IGF2 expression and secretion (Fig. 6A, left and Supplementary Fig. 341 
S11), and obtained consistent data showing that knockdown of IGF2 significantly reduced p-342 
AKT and TS expressions, increased 5-FU-induced cell death and cleaved caspase-3 343 
expression compared with non-target control (shCON) (Fig. 6A), indicating restored 344 
sensitivity of FR cells to 5-FU by IGF2 silencing. These effects were revoked by addition of 345 
exogenous IGF2 to the culture media of IGF2-knockdown FR cells. Moreover, stable 346 
knockdown of IGF2 in two ESCC cell lines with relatively high endogenous IGF2 expression 347 
and 5-FU chemoresistance rendered the cells more apoptotic and sensitive to 5-FU treatment 348 
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(Supplementary Fig. S12A-D). The significance of IGF2 in chemoresistance was also tested 349 
in vivo. The results showed that knockdown of IGF2 significantly reduced the resistance of 350 
KYSE410FR and KYSE270FR tumors to 5-FU treatment in mice, as evidenced by the 351 
decreased tumor volume compared with the respective 5-FU-refractory control groups (Fig. 352 
6B and Supplementary Fig. S12E), thus confirming that IGF2 plays an important role in 353 
acquired 5-FU chemoresistance. Furthermore, we found that blockade of IGF2 with shRNA 354 
or neutralizing antibody attenuated the effects of Id1 and E2F1 in increasing 5-FU 355 
chemoresistance (Fig. 6C). Taken together, these data suggest that IGF2 upregulates TS 356 
expression and thus enhances 5-FU chemoresistance in Id1-overexpressing tumors by 357 
signaling through the PI3K/AKT pathway (Fig. 6D).   358 
 359 
High expression of Id1 and IGF2 is correlated with poor survival in cancer patients  360 
Given that Id1 and IGF2 play important roles in regulating 5-FU chemoresistance, we 361 
postulated that Id1 and IGF2 may be potential prognostic markers for cancer patients. We 362 
therefore investigated whether a high level of Id1 and IGF2 expression in cancer is associated 363 
with survival of cancer patients. Firstly, expression levels of Id1 and IGF2 in ESCC were 364 
determined using qRT-PCR in a cohort of esophageal cancer patients with survival data, and 365 
the results showed that the patients with high Id1 and IGF2 expression had shorter survival 366 
(median survival = 15.61 months) than patients with low Id1 and IGF2 expression (median 367 
survival = 29.77 months). Log-rank analysis showed that high Id1 and IGF2 mRNA level 368 
was significantly correlated with shorter survival (Log rank = 4.880, P = 0.027; Fig. 6E), 369 
although it was not correlated with tumor stage or tumor differentiation (Supplementary 370 
Table S1). Likewise, analysis of colon cancer patient cohort from GEO datasets revealed that 371 
patients with high Id1 and IGF2 expression had shorter survival (median survival = 49.2 372 
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months) than patients with low Id1 and IGF2 expression (median survival = 85.3 months), 373 
with a significant correlation between concurrent high Id1/IGF2 mRNA level and shorter 374 
survival (Log rank = 6.534, P = 0.011). Similar results were obtained in cohorts of HCC, lung 375 
cancer, and breast cancer patients (Fig. 6F). Collectively, our results indicated that concurrent 376 
high expression of Id1 and IGF2 may predict poor prognosis of cancer patients.  377 
378 
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Discussion 379 
Acquired chemoresistance contributes to poor treatment response and cancer recurrence. 380 
Chemoresistant cancer cell lines have been successfully used as models to efficiently identify 381 
key genes and signaling pathways associated with chemoresistance in human cancer (28-30). 382 
Establishment of chemoresistant cell lines from chemosensitive parental human ESCC cells 383 
in vitro mimics the in vivo process in which esophageal tumors acquire resistance to cytotoxic 384 
drugs after initial chemotherapy. A combination of 5-FU and cisplatin is one of the most 385 
commonly used regimens as first-line treatment of advanced esophageal cancer. The FR cells 386 
established in our laboratory showed increase in expression levels of Id1, IGF2, and E2F1. 387 
E2F1 has been documented to directly activate TS transcription and expression (6). The 388 
positive correlation between E2F1 and TS expression, and the association between E2F1 389 
overexpression and poor prognosis in a variety of cancers including ESCC have been 390 
reported (31-33). By confirming the role of E2F1 in conferring 5-FU chemoresistance in 391 
esophageal cancer cells, we have justified the use of FR cell models as tools for identification 392 
of chemoresistance-associated genes and novel drug targets. Here, we report for the first time 393 
that Id1 can increase TS expression and promote 5-FU chemoresistance in human cancer, and 394 
that E2F1 mediates this effect. To our knowledge, this is the first report on the function of Id1 395 
in ESCC chemoresistance. 396 
 397 
E2F1 has primarily been recognized for its pivotal role in transcriptional regulation of 398 
genes related to cell cycle and apoptosis. Dysregulation of E2F1 is common in human cancer 399 
including esophageal cancer (34),  but amplification of E2F1 in cancer is rare. As in the case 400 
for many transcription factors, E2F1 is mainly regulated by post-translational modification. 401 
The pRb protein, which functionally inactivates E2F1 on one hand but protects it from 402 
degradation on the other, was thought to be the most crucial regulator of E2F1 (35). However, 403 
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after dissociation from pRb, interaction with other proteins may be vital for the stability of 404 
E2F1 protein. In this study, the gain- and loss-of-function experiments showed that ectopic 405 
Id1 expression induced, whereas Id1 knockdown reduced, the expression of E2F1 in multiple 406 
cancer cell lines, thus strongly suggesting that Id1 can regulate E2F1. Our results from CHX 407 
chase and immunoprecipitation experiments give novel insight into the regulation of E2F1 by 408 
providing the first evidence that Id1 competes with E2F1 for Cdc20 binding, thereby 409 
protecting E2F1 from Cdc20-mediated degradation. As discussed below, our data also 410 
revealed that this mechanism plays an important role in upregulating IGF2 in esophageal 411 
cancer. 412 
 413 
Overexpression of IGF2 and its clinical significance in human cancer is well documented 414 
(36-38). Increased IGF2 expression in Taxol-resistant ovarian cancer cell line and the 415 
feasibility of IGF2 as a potential therapeutic target in Taxol-resistant ovarian cancer have 416 
been validated recently (39-41), but the functional role of IGF2 in 5-FU chemoresistance has 417 
not been elucidated. We found for the first time that IGF2 can significantly increase, whereas 418 
knockdown of IGF2 can decrease, TS expression. E2F1 is an important target of 419 
chemotherapeutic drugs, and aberrant expression of TS is significantly associated with the 420 
resistance of tumors to chemotherapy (42, 43). Our data showed that both intrinsic and 421 
acquired 5-FU chemoresistance of ESCC cells could be achieved by knocking down IGF2 to 422 
reduce TS expression. In addition, our in vitro and in vivo data from gain- and loss-of-423 
function experiments provide novel evidence to support that IGF2 plays an important role in 424 
mediating the effects of Id1 in regulating the sensitivity of cancer cells to 5-FU. We recently 425 
reported that Id1 induces IGF2 expression and secretion (1), but the molecular mechanisms 426 
by which Id1 regulates IGF2 is still unknown. In this study, using ChIP, dual luciferase 427 
reporter, and rescue assays, we show for the first time that E2F1 mediates the positive 428 
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regulation of Id1 on IGF2 by directly binding to the IGF2 promoter, thereby activating IGF2 429 
transcription and expression. 430 
 431 
 Overall, our results suggest that besides directly inducing the transcription and expression 432 
of TS, there exists a parallel mechanism in which Id1 and E2F1 can indirectly upregulate TS 433 
by transcriptional activation of IGF2, thus engaging the PI3K/AKT pathway in mediating 5-434 
FU chemoresistance. The strong positive correlation between Id1 and E2F1, and between 435 
E2F1 and IGF2 protein expressions observed in esophageal tumor tissues, as well as between 436 
Id1 and IGF2 mRNA expressions in esophageal cancer and a variety of other cancer types 437 
further suggest that this regulatory mechanism has clinical significance in human cancer. 438 
More importantly, analysis of gene expression profiles of multiple cancer types indicated that 439 
simultaneous high Id1 and IGF2 expression in the tumors is significantly correlated with 440 
shorter survival of cancer patients. Taken together, this study suggests that dysregulation of 441 
E2F1 and IGF2 due to Id1 overexpression is important in cancer progression, and that the 442 
Id1-E2F1-IGF2 regulatory axis may be a valid gene expression signature for prognostic 443 
prediction and a target for new treatment strategies. 444 
  445 
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Figure Legends 597 
Figure 1. 5-FU-resistant (FR) esophageal cancer sublines have increased expression of Id1, 598 
IGF2 and E2F1, and form 5-FU-resistant tumors in vivo. A, diagram depicting the 599 
establishment of FR sublines from esophageal cancer cells. B, nude mice bearing 600 
KYSE410FR- or KYSE410-derived tumor xenografts were treated with 5-FU (20 mg/kg) 601 
twice weekly for three weeks (n = 6). C and D, FR cells and parental cells were compared for 602 
expression levels of Id1, IGF2, and E2F1 in cell lysate by Western blot (C) and for IGF2 603 
concentration in the conditioned medium by ELISA (D). E, the mRNA expression levels of 604 
Id1, E2F1, and IGF2 were determined in FR cells and parental cells by real-time RT-PCR. 605 
Bars, SD; **, P < 0.01; ***, P < 0.001. 606 
 607 
Figure 2. Id1 increases thymidylate synthase (TS) expression and 5-FU chemoresistance 608 
through E2F1. A and B, KYSE150 and KYSE410 cells were transfected with different doses 609 
of pcDNA3-Id1 supplemented with pcDNA3 (A), whereas KYSE150FR and KYSE410FR 610 
cells were transfected with siRNA against Id1 or the vector expressing shRNA against Id1 611 
(B), then Western blot was performed. C, E2F1 knockdown markedly abrogated the effects 612 
of Id1 overexpression on TS expression, whereas E2F1 re-overexpression significantly 613 
alleviated the inhibitory effects of Id1 knockdown on TS expression. D, the expression levels 614 
of Id1 and E2F1, determined using Western blot, were significantly correlated in the 50 pairs 615 
of human esophageal tumor and normal specimens. Right panel, Western blot of Id1, E2F1 616 
and actin in six representative pairs of esophageal tumor tissues (T) and their matched normal 617 
tissues (N). E, parental and FR esophageal cancer cells with stable expression of indicated 618 
plasmids were treated with 5-FU (10 μM) or DMSO for 48 h and then subjected to BrdU 619 
incorporation assay. F, left panel, comparison of KYSE410-CON, KYSE410-Id1, and 620 
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KYSE410-Id1-shE2F1 tumor xenografts for 5-FU sensitivity in nude mice (n = 6). Right 621 
Panel, E2F1 overexpression counteracted the inhibitory effect of Id1-knockdown on 5-FU 622 
chemoresistance of KYSE410FR tumors in nude mice (n = 6). Bars, SD; *, P < 0.05; **, P < 623 
0.01; ***, P < 0.001.  624 
 625 
Figure 3. Id1 protects E2F1 protein from degradation through competitive binding to Cdc20. 626 
A, KYSE150-Id1, KYSE410-Id1 and their respective vector control cells were treated with 627 
cycloheximide (CHX, 50 μg/ml). The cell lysates were collected at the indicated time points 628 
and compared for E2F1 expressing using Western blot. E2F1 signals were quantified by 629 
densitometry and the degradation rate was shown as the ratio of E2F1 level at each time point 630 
to the respectively original level (0 h). The half-life (t1/2) of E2F1 was 6.08 h and 3.01 h in 631 
Id1-overexpressing KYSE150 cells and corresponding vector control cells respectively; t1/2 632 
values were 13.23 h and 3.97 h in Id1-overexpressing KYSE410 cells and vector control cells 633 
respectively. B and C, the indicated Flag/HA-tagged plasmids or pcDNA3 empty vector were 634 
transfected into KYSE150 cells. Immunoprecipitation was performed using an anti-Flag 635 
antibody or IgG as control, and Western blot carried out on the total cell lysate or 636 
immunoprecipitate using the indicated antibodies showed that Cdc20 co-immunoprecipitated 637 
with Id1 and E2F1. D, the constructs expressing Flag-tagged Cdc20 and HA-tagged E2F1 638 
were co-transfected with HA-tagged Id1 construct or vector control into KYSE150 cells. 639 
Immunoprecipitation assay was performed on the cell lysates using an anti-Flag antibody or 640 
IgG as a control, followed by Western blot to detect protein expressions. E, a proposed model 641 
illustrating the mechanism by which Id1 induces E2F1 stabilization through competitive 642 
binding with Cdc20 to activate IGF2 transcription and expression. 643 
 644 
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Figure 4. E2F1 directly binds to IGF2 promoter and increases IGF2 transcription and 645 
expression, thereby mediating the regulation of IGF2 by Id1. A and B, Western blot (A) and  646 
RT-PCR (B) analyses of IGF2 in the esophageal cancer cells transfected with different doses 647 
of pcDNA3-E2F1, or plasmids expressing shE2F1#1 or shE2F1#2. The pcDNA3 empty 648 
vector was transfected as control. C, upper panel, schematic illustration of putative E2F1-649 
binding sites in the IGF2 promoter region. TSS represents transcription start site. BS1, BS2, 650 
and BS3 indicate the predicted E2F1-binding sites. Lower panel, ChIP assay was conducted 651 
to pull down potential E2F1-binding DNA fragments in KYSE270 cells using E2F1 antibody 652 
or IgG antibody. qPCR was performed to determine the abundance of DNA fragments in the 653 
putative IGF2 promoter region. D, upper panel, a diagram representing the IGF2 promoter 654 
region inserted upstream of firefly luciferase gene in pGL2-basic vector, and the mutations at 655 
the predicted E2F1-binding sequences. Lower panel, E2F1-expressing plasmid or vector 656 
control was co-transfected with the wild type (WT) or mutant reporter construct into 657 
KYSE150 cells, and luciferase activity was measured 48 h after transfection. E, Western 658 
blots of KYSE150 and KYSE410 cells that were co-transfected with Id1-expression or pBabe 659 
control vector, and indicated plasmids expressing shE2F1#1, shE2F1#2 or shCON performed. 660 
F, Western blot indicated that knockdown of Id1 inhibited E2F1 and IGF2 expressions in 661 
KYSE270 and T.Tn cells, and that transfection with E2F1-expressing plasmid abolished this 662 
effect. Bars, SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with control cells unless 663 
otherwise indicated. 664 
 665 
Figure 5. Positive correlation between E2F1 and IGF2 in human cancers. A, IGF2 and actin 666 
expressions were determined in 50 pairs of esophageal tumor and matched normal tissues by 667 
Western blot and densitometry. The boxes in the right panels contain the values between 25th 668 
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and 75th percentiles of the 50 cases, and the whiskers extend to the highest and lowest values. 669 
The lines across the boxes indicate the median values, and the white diamonds inside the 670 
boxes represent the mean values. B, the expression levels of E2F1 and IGF2 were 671 
significantly correlated in the 50 pairs of human esophageal tumor and normal specimens. 672 
Right panel, Western blot of E2F1, IGF2 and actin in six representative pairs of esophageal 673 
tumor tissues (T) and their matched normal tissues (N). C, two consecutive sections of a 674 
human ESCC tissue microarray were immunostained for E2F1 and IGF2 expression. The 675 
correlation between the immunostaining intensity of the proteins was determined by Fisher’s 676 
Exact test (left panel), and two representative cases showing strong (Case 1) and weak (Case 677 
2) staining are shown in the right panel. D, Gene Expression Omnibus (GEO) cancer datasets 678 
were acquired for analyzing the correlation between relative levels of E2F1 and IGF2 mRNA 679 
using Pearson’s rank correlation coefficient analysis. E2F1 and IGF2 expressions were 680 
significantly correlated in all the datasets examined in this study including ESCC 681 
(GSE23400/47404), EAC (GSE13898/37203), colon cancer (GSE28000/28722), HCC 682 
(GSE10141/45436/54236), lung cancer (GSE3141), and breast cancer (GSE7849/50948).  683 
 684 
Figure 6. Significance of IGF2 in 5-FU chemoresistance and impact of high Id1 and IGF2 685 
expression on survival of cancer patients. A, left panel, Western blot showed that IGF2 686 
knockdown significantly reduced p-AKT and thymidylate synthase (TS) expressions. Middle 687 
and right panels, the FR cells stably transfected with shIGF2 or non-effective shRNA 688 
expression plasmids were treated with 5-FU (20 μM) or DMSO in the presence or absence of 689 
exogenous IGF2 (50 ng/ml) for four days; cell proliferation was determined by BrdU 690 
incorporation assay, and the expression levels of caspase-3 and cleaved caspase-3 were 691 
compared by Western blot. B, 5-FU treatment for three weeks significantly reduced the size 692 
32 
 
of the KYSE410FR-shIGF2 tumors, but not the KYSE410FR-shCON tumors (n = 6). C, 693 
esophageal cancer cells with ectopic Id1 (left panel) or E2F1 (right panel) expression and the 694 
vector control cells were treated with 5-FU (10 μM) or DMSO for 48 h, and cell proliferation 695 
compared using BrdU incorporation assay. Note that shRNA or neutralizing antibody against 696 
IGF2 (0.5 μg/ml) ameliorated the Id1- and E2F1-induced chemoresistance to 5-FU. D, 697 
proposed model illustrating the regulatory roles of Id1 and IGF2 in 5-FU chemoresistance. E, 698 
Kaplan-Meier curves comparing survival rates of ESCC patients (n = 35) dichotomized into 699 
high Id1/high IGF2- and low Id1/low IGF2-expressing groups. F, Kaplan-Meier plots based 700 
on GEO datasets of colon cancer (GSE28722; n = 125), HCC (GSE54236; n = 81), lung 701 
cancer (GSE3141; n = 111), and breast cancer (GSE7849; n = 78) patients.  The results 702 
consistently showed that high Id1 and IGF2 expression is significantly associated with shorter 703 
survival. Bars, SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with control cells 704 
unless otherwise indicated. 705 
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